NYSE:EBSEmergent Biosolutions Stock Price, Forecast & News

$86.91

+2.09 (+2.46 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$83.65

Now: $86.91▼

$87.81

50-Day Range

$62.58

MA: $79.05▼

$89.52

52-Week Range

$39.11

Now: $86.91▼

$93.58

Volume530,527 shs

Average Volume525,427 shs

Market Capitalization$4.56 billion

P/E Ratio66.85

Dividend YieldN/A

Beta1.27

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; RSDL (Reactive Skin Decontamination Lotion Kit), a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard for intramuscular self-injection of atropine sulfate and obidoxime chloride. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for treating botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. Further, it provides NuThrax, an anthrax vaccine; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; ADENOVIRUS 4/7, a live attenuated vaccine; rVSV-Lassa, a vaccine for prevention of Lassa fever; rVSV-Marburg, a vaccine for prevention of Marburg hemorrhagic fever; rVSV-Sudan, vaccine for prevention of Sudan hemorrhagic fever; rVSV-QUAD, a vaccine for prevention of hemorrhagic fever; and rVSV-Ebola, a vaccine for prevention of Ebola hemorrhagic fever. Additionally, the company offers FLU-IGIV to treat Influenza A infection in hospitalized patients; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract manufacturing services to third-party customers. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.

Beat the Market (BTM) Rank^™

2.4 Analyst's Opinion

Consensus Rating
Emergent Biosolutions has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $83.86, Emergent Biosolutions has a potential downside of 3.5% from its current price of $86.91.
Amount of Analyst Coverage
Emergent Biosolutions has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Emergent Biosolutions has received 389 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Emergent Biosolutions has received 338 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Emergent Biosolutions has received 53.51% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote “Outperform” if you believe EBS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Emergent Biosolutions does not currently pay a dividend.
Dividend Growth
Emergent Biosolutions does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,322,937.00 in company stock.
Percentage Held by Insiders
Only 14.10% of the stock of Emergent Biosolutions is held by insiders.
Percentage Held by Institutions
85.61% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Emergent Biosolutions are expected to grow by 7.03% in the coming year, from $3.13 to $3.35 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Emergent Biosolutions is 66.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.59.
Price to Earnings Ratio vs. Sector
The P/E ratio of Emergent Biosolutions is 66.85, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.03.
Price to Book Value per Share Ratio
Emergent Biosolutions has a P/B Ratio of 4.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.35 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNYSE:EBS

Previous Symbol

CUSIP29089Q10

CIK1367644

Webwww.emergentbiosolutions.com

Phone240-631-3200

Debt

Debt-to-Equity Ratio0.71

Current Ratio3.03

Quick Ratio1.83

Price-To-Earnings

Trailing P/E Ratio66.85

Forward P/E Ratio27.77

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.11 billion

Price / Sales4.12

Cash Flow$5.28 per share

Price / Cash Flow16.46

Book Value$21.08 per share

Price / Book4.12

Profitability

EPS (Most Recent Fiscal Year)$2.91

Net Income$54.50 million

Net Margins6.15%

Return on Equity14.58%

Return on Assets6.59%

Miscellaneous

Employees1,834

Outstanding Shares52,430,000

Market Cap$4.56 billion

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions

How has Emergent Biosolutions' stock been impacted by COVID-19 (Coronavirus)?

Emergent Biosolutions' stock was trading at $53.03 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EBS shares have increased by 63.9% and is now trading at $86.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Emergent Biosolutions?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Emergent Biosolutions.

When is Emergent Biosolutions' next earnings date?

Emergent Biosolutions is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Emergent Biosolutions.

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions Inc (NYSE:EBS) released its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported $0.01 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.01. The biopharmaceutical company had revenue of $192.50 million for the quarter, compared to the consensus estimate of $198.79 million. Emergent Biosolutions had a net margin of 6.15% and a return on equity of 14.58%. The firm's quarterly revenue was up 1.0% on a year-over-year basis. During the same period last year, the firm posted ($0.13) earnings per share. View Emergent Biosolutions' earnings history.

What guidance has Emergent Biosolutions issued on next quarter's earnings?

Emergent Biosolutions updated its second quarter 2020 After-Hours earnings guidance on Thursday, April, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $270-300 million, compared to the consensus revenue estimate of $289.51 million.

What price target have analysts set for EBS?

7 brokers have issued 1 year target prices for Emergent Biosolutions' stock. Their forecasts range from $67.00 to $101.00. On average, they expect Emergent Biosolutions' stock price to reach $83.86 in the next year. This suggests that the stock has a possible downside of 3.5%. View analysts' price targets for Emergent Biosolutions.

Has Emergent Biosolutions been receiving favorable news coverage?

Media stories about EBS stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Emergent Biosolutions earned a daily sentiment score of 3.0 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutEmergent Biosolutions.

Who are some of Emergent Biosolutions' key competitors?

Some companies that are related to Emergent Biosolutions include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of Emergent Biosolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Gilead Sciences (GILD), Mercadolibre (MELI), NVIDIA (NVDA), Broadcom (AVGO), Micron Technology (MU), Intel (INTC), Alibaba Group (BABA), salesforce.com (CRM), Johnson & Johnson (JNJ) and Netflix (NFLX).

Who are Emergent Biosolutions' key executives?

Emergent Biosolutions' management team includes the following people:

Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)
Mr. Robert G. Kramer Sr., CEO, Pres & Director (Age 62)
Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 55)
Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)
Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48)

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent Biosolutions' major shareholders?

Emergent Biosolutions' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.72%), State Street Corp (4.15%), Invesco Ltd. (1.74%), The Manufacturers Life Insurance Company (1.72%), Rice Hall James & Associates LLC (1.46%) and Atlanta Capital Management Co. L L C (1.37%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View institutional ownership trends for Emergent Biosolutions.

Which institutional investors are selling Emergent Biosolutions stock?

EBS stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, BlackRock Inc., Vaughan Nelson Investment Management L.P., Jennison Associates LLC, Morgan Stanley, Morgan Stanley, Eaton Vance Management, and Silvercrest Asset Management Group LLC. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Fuad El-Hibri, Kathryn C Zoon, Ronald Richard, Sue Bailey, and Zsolt Harsanyi. View insider buying and selling activity for Emergent Biosolutions.

Which institutional investors are buying Emergent Biosolutions stock?

EBS stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., The Manufacturers Life Insurance Company , Loomis Sayles & Co. L P, Copper Rock Capital Partners LLC, Family Firm Inc., New York State Common Retirement Fund, Wells Fargo & Company MN, and Atlanta Capital Management Co. L L C. View insider buying and selling activity for Emergent Biosolutions.

How do I buy shares of Emergent Biosolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Emergent Biosolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $86.91.

How big of a company is Emergent Biosolutions?

Emergent Biosolutions has a market capitalization of $4.56 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $54.50 million in net income (profit) each year or $2.91 on an earnings per share basis. Emergent Biosolutions employs 1,834 workers across the globe.

What is Emergent Biosolutions' official website?

The official website for Emergent Biosolutions is www.emergentbiosolutions.com.

How can I contact Emergent Biosolutions?

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff